News

December 13, 2017December 13, 2017

RoActemra, IL-1 Inhibitors Better Than Enbrel to Manage JA, Study Suggests

News

RoActemra (tocilizumab) or IL-1 inhibitors are more effective than Enbrel in managing and promoting remission in patients with juvenile idiopathic arthritis (JIA), according to a study published in the journal ... Read more

December 8, 2017December 8, 2017

Frequency of Remission in Juvenile Idiopathic Arthritis Rises with Disease Duration, Review Study Shows

News

Among patients with juvenile idiopathic arthritis (JIA), those who have a longer disease duration — up to 10 years — are more likely to achieve remission, a review study suggests. ... Read more

December 6, 2017December 6, 2017

Older Age, Disability, Longer Disease Duration Are Risk Factors for Greater Pain in JIA Patients

News

Juvenile idiopathic arthritis (JIA) patients who are older at disease onset, have poor functioning or disability, and have a longer disease duration consistently experience greater levels of pain, new research ... Read more

December 1, 2017December 1, 2017

JIA Increases Risk of Pregnancy Complications, Swedish Study Suggests

News

Women with juvenile idiopathic arthritis (JIA) who become pregnant should be closely monitored by doctors, as they have an increased risk of both maternal and infant complications, according to a new ... Read more

November 29, 2017November 29, 2017

Biosimiliar Erelzi Now Available in 2 Canadian Provinces for Arthritis, Other Inflammatory Conditions

News

British Columbia and Prince Edward Island have become the first Canadian provinces to add Erelzi (etanercept), a biosimilar of Amgen‘s Enbrel, to the public drug plans for the treatment of inflammatory ... Read more

November 22, 2017November 22, 2017

Amgen Launches Enbrel Mini Single-dose Prefilled Cartridge with Reusable Autoinjector

News

Amgen‘s Enbrel Mini with AutoTouch is now available in the United States for the treatment of chronic conditions like polyarticular juvenile idiopathic arthritis (JIA), rheumatoid arthritis, and other conditions. Enbrel (etanercept) ... Read more

November 17, 2017November 17, 2017

US Phase 3 Trial Evaluating Efficacy of Sobis’ Kineret Gets Underway

News

The first patients have started receiving treatment in a Phase 3 trial evaluating the therapeutic potential of Kineret (anakinra) for adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA). AOSD ... Read more

November 15, 2017November 15, 2017

Humira Biosimilar Cyltezo Approved in Europe to Treat Chronic Inflammatory Diseases

News

The European Commission has granted marketing authorization for Cyltezo, a biosimilar to Humira (adalimumab) developed by Boehringer Ingelheim, for adults and children with several chronic inflammatory diseases including juvenile arthritis. The ... Read more

November 8, 2017November 8, 2017

Teens with Juvenile Arthritis Find Help in Online Educational Program

News

The online educational site Taking Charge: Managing JIA Online, together with monthly calls from health coaches, can help teenagers with juvenile idiopathic arthritis (JIA) better cope with their disease, according ... Read more

November 3, 2017November 3, 2017

Momenta and Mylan’s Biosimilar Candidate M834 Misses Initial Trial Goals

News

Momenta Pharmaceuticals and Mylan recently reported that M834, a biosimilar candidate for abatacept designed to treat autoimmune diseases, did not meet its primary pharmacokinetic (PK) goals in a direct comparison study with Orencia ... Read more